Air quality alert issued for all of Michigan Wednesday and Thursday because of Canadian wildfires
There is an air quality alert for all counties in Michigan until midnight Friday, the Michigan Department of Environment, Great Lakes and Energy reported. Pollutants across the state are expected to be in the Unhealthy for Sensitive Groups (USG, Orange AQI) range Wednesday and Thursday with some locations reaching the Unhealthy (Red AQI) range.
This is what is contributing to poor air quality for Wednesday and Thursday.
Wildfire smoke from Canada moved into the Upper Peninsula of Michigan on Tuesday and the Lower Peninsula on Wednesday morning.
Anyone with respiratory issues or trouble breathing will need to try staying indoors as much as possible until Friday.
Monitor any coughing or problems breathing.
Try not to burn anything outdoors and keep windows closed overnight.
Rain along a front and winds behind it will help to move some, if not all, of the smoke out by the end of the week.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
7 minutes ago
- Associated Press
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products
WILMINGTON, Del., Aug. 4, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced the filing of a Citizen Petition with the US Food and Drug Administration (FDA), seeking the removal of Benzethonium Chloride from all forms of ketamine sold in the United States. Benzethonium Chloride (BZT) is a preservative with known toxicity that is not Generally Recognized as Safe (GRAS) by the FDA for parenteral products and not Generally Recognized as Safe and Effective (GRASE) for topical products. It belongs to a class of quaternary amine preservatives that is known to be toxic to epithelial cells and to demonstrate neurotoxicity. This class of preservatives has been removed from many eyedrops because of demonstrated toxicity to the conjunctiva and corneal nerves. The FDA no longer allows BZT to be used in hand cleansers and topical antiseptics.1 In June 2025 NRx filed an Abbreviated New Drug Application with the FDA for a preservative-free preparation of ketamine, demonstrating support for 3 year room temperature stability and sterility. NRx has similarly filed a patent on its preservative-free process, in light of prior art that suggested BZT was required for long term stability and sterility. The Company has instituted US-based high volume manufacture, while it awaits generic approval. The Company is additionally seeking a labeled indication for the use of ketamine to treat suicidal depression through the recently-announced FDA Commissioner's National Priority Voucher Program. 'At its introduction in the 1970s, ketamine was developed as an anesthetic and was never intended to be administered repeatedly to patients,' said Dr. Jonathan Javitt, CEO of NRx Pharmaceuticals. 'Ketamine is now widely used on a repeated basis as the only currently marketed drug that has shown benefit in treating suicidal depression and PTSD, although this is currently not a labeled indication. Hence, patients who receive intravenous ketamine on a repeated basis are exposed to a known toxic preservative that cannot be used today in hand cleaner, antiseptics, and other topical products. The European Medicines Agency has warned against its use.2 We believe that our Citizen Petition aligns with priorities articulated by current leadership of the US Department of Health and Human Services to remove potentially toxic additives and preservatives from the US Food and Drug supply and to re-shore the US Drug Supply.' About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRx has recently filed an Abbreviated New Drug Application (ANDA) for preservative-free ketamine and initiated a New Drug Application filing for NRX-100 (IV ketamine) under the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'believe,' 'intend,' 'look forward,' and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: 1 U.S. Food and Drug Administration. Final Rule: Safety and Effectiveness of Consumer Antiseptic Wash Products. 81 FR 61106. September 6, 2016. 2 European Medicines Agency (EMA). (2020). Questions and answers on benzalkonium chloride used as an excipient in medicinal products for human use [PDF]. EMA. View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc.
Associated Press
7 minutes ago
- Associated Press
Hyperfine Achieves Clinical Milestone Ahead of Plan With 100th Patient Enrolled in Neurology Office Study Using the Next-Generation Swoop® System
GUILFORD, Conn.--(BUSINESS WIRE)--Aug 4, 2025-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system— today announced the successful enrollment of 100 patients in its NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study just 16 weeks after the study initiation, announced on April 15, 2025. This milestone reflects strong clinician enthusiasm for accessible, point-of-care brain imaging and supports Hyperfine's market expansion into outpatient neurology offices. This press release features multimedia. View the full release here: The NEURO PMR study, being conducted at DENT Neurologic Institute and Texas Neurology, is the first multi-center, prospective observational study comparing portable ultra-low-field MRI with conventional high-field MRI in neurology office settings. All patients enrolled in the study have been scanned on the next-generation Swoop® system powered by OptiveAI™ software, with results expected to be announced in early 2026. Dr. Laszlo Mechtler, Chief Medical Officer at DENT Neurologic Institute and the study's Principal Investigator, stated, 'The next-generation Swoop® system delivers impressive image quality with a simplified clinic workflow and comfortable patient experience. The promise of this technology is that it puts brain imaging back into the hands of neurologists—by providing an affordable, easy-to-operate portable MRI system that fits seamlessly into a clinic setting without expensive siting costs.' This milestone supports Hyperfine's commercial launch in the neurology office market, following the successful conclusion of its office pilot program. In the pilot, early neurology practices acquired and implemented Swoop® systems in their clinic, completed IAC accreditation, and obtained reimbursement from CMS and private insurers. To drive commercial adoption, Hyperfine has also entered into a strategic partnership with NeuroNet Pro, the largest U.S. association of independent neurology practices, to bring greater awareness and practice support for their portable MRI technology. 'Neurologists typically order between 500 and 600 brain MRIs each year, yet only 5% of private neurology offices have in-house imaging,' said Maria Sainz, President and CEO of Hyperfine. 'Our next-generation Swoop® system delivers an exciting opportunity for independent practices—expanding access to advanced imaging, boosting clinic efficiency, and elevating the level of patient care.' For more information about the Swoop® system and Optive AI™ software, please visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. View source version on CONTACT: Media Contact Devin Zell Hyperfine [email protected] Contact Webb Campbell Gilmartin Group LLC [email protected] KEYWORD: UNITED STATES NORTH AMERICA CONNECTICUT INDUSTRY KEYWORD: FDA HEALTH TECHNOLOGY DATA MANAGEMENT TECHNOLOGY RADIOLOGY MANAGED CARE GENERAL HEALTH MEDICAL DEVICES NEUROLOGY ARTIFICIAL INTELLIGENCE CLINICAL TRIALS SCIENCE SOFTWARE HEALTH RESEARCH SOURCE: Hyperfine, Inc. Copyright Business Wire 2025. PUB: 08/04/2025 08:15 AM/DISC: 08/04/2025 08:14 AM
Associated Press
7 minutes ago
- Associated Press
Flex Partners with Dermstore to Expand Access to Dermatologist-Recommended Skincare with HSA/FSA Payments
Customers can now use HSA/FSA funds on eligible skincare and health products at NEW YORK, Aug. 4, 2025 /PRNewswire/ -- Online beauty retailer Dermstore, a trusted consumer education and shopping destination, has partnered with Flex, the leading HSA/FSA payment solution for health and wellness brands, to make it easier for customers to purchase eligible beauty products using pre-tax healthcare dollars. Dermstore is one of the first beauty e-commerce sites to offer seamless HSA/FSA compatibility at checkout. Through this innovative partnership, customers can now use Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) cards directly at checkout on Dermstore, expanding the accessibility of using pre-tax savings across their suite of expert-backed, professional-strength products—including brands like SkinCeuticals, EltaMD, SkinMedica, Medik8, and Eminence Organic Skin Care. 'Accepting HSA/FSA cards at checkout is a key milestone for us in our commitment to supporting beauty shoppers to invest in their own skin health routines, and we are proud to be among the first beauty-focused e-commerce platforms to do so,' said James Bonner, President of U.S. Retail at Dermstore. 'We chose Flex for their capabilities, alignment with our goals, and shared commitment to delivering a seamless payment experience. We believe our community should be able to invest their HSA/FSA dollars in the preventative health benefits of our assortment, and through this partnership, it's great to unlock that benefit for them.' Flex works behind the scenes to help brands like Dermstore navigate IRS eligibility guidelines and streamline HSA/FSA acceptance online. With built-in verification tools and optional support for Letters of Medical Necessity, Flex ensures that customers can confidently use their HSA/FSA funds for eligible purchases—without needing to submit claims or paperwork after checkout. 'Skincare is healthcare for millions of Americans—especially when it's medically recommended or used to treat a specific condition,' said Sam O'Keefe, CEO of Flex. 'Dermstore is a leader in trusted, high-quality products, and we're proud to help make those more accessible through HSA/FSA payment options.' Whether managing chronic skin conditions, addressing post-procedure care, or simply prioritizing wellness through expert-vetted products, Dermstore customers now have a more affordable way to invest in their health through Flex. About Dermstore Dermstore was founded by a dermatologist in 1999 to give patients access to medical-grade skin care online. Today, we focus on making professional-strength products accessible and approachable as a trusted, authorized retailer. We offer efficacious formulas from top skin care brands, hard-to-find spa and beauty brands, as well as professional hair care and makeup by specialty brands from around the world. It serves as an online source of discovery and education, bringing together top experts, the industry's most efficacious brands and a passionate community of skin-health-seeking consumers. Dermstore's mission is to help people honor their skin by prioritizing skin health. Learn more at About Flex Flex is the HSA/FSA payments infrastructure for top health and wellness brands. Built for omnichannel retailers, Flex helps businesses unlock over $150B in pre-tax health spending—boosting AOV by up to 50% without adding new acquisition channels. From recurring payments to mixed-eligibility carts, Flex integrates seamlessly into your existing tech stack and handles the complexity of HSA/FSA so your team doesn't have to. Learn more at View original content to download multimedia: SOURCE Dermstore
